FDA

May 29, 2019

UAMS, International Collaborators Use FDA-Approved Drugs to Extend Life in Worms

David Robinson

Robert Reis, D.Phil., led the UAMS team that helped identify FDA-approved drugs that can extend life in nematodes

An international research collaboration that includes the University of Arkansas for Medical Sciences (UAMS) has discovered that aging in nematodes (worms) can be slowed and even reversed by a number of Food and Drug Administration (FDA)-approved drugs, findings that have the potential to extend human lifespan. The study findings are published in Scientific Reports. The…

February 20, 2018

Based on UAMS Research, InterveXion Wins Grants, Partners with BioVentures’ Help

Ben Boulden

Misty Stevens demonstrates one of the lab procedures InterveXion uses in the development of the monoclonal antibody it is studying for possible future use in the treatment of methamphetamine addiction.

Feb. 20, 2018 | Truly good ideas like the one around which InterveXion was built have staying power. Since InterveXion was established as a company in 2004, granting agencies and others have continued to value both the company and its mission. BioVentures from the first saw merit in the new treatment for methamphetamine abuse developed…

July 30, 2014

UAMS’ Barone Named to FDA Tobacco Products Advisory Panel

Spencer Watson

LITTLE ROCK – Claudia Barone, Ed.D., A.P.R.N., a professor in the College of Nursing at the University of Arkansas for Medical Sciences (UAMS), has become the first nurse appointed to the Tobacco Products Scientific Advisory Committee of the U.S. Department of Health and Human Services, Food and Drug Administration (FDA).

May 12, 2014

UAMS Drug Trial Leads to First FDA-Approved Treatment for Blood Disorder Called Castleman’s Disease

Nate Hinkel

LITTLE ROCK – The first-ever treatment for a rare blood disorder called multicentric Castleman’s disease was approved recently by the Food and Drug Administration after drug trials headed by a researcher at the University of Arkansas for Medical Sciences (UAMS).

October 8, 2013

UAMS Awarded $8.7 Million Contract for Radiation Research

Ben Boulden

Oct. 8, 2013 | The Biomedical Advanced Research and Development Authority (BARDA) has exercised two contract options worth approximately $8.7 million with the University of Arkansas for Medical Sciences (UAMS) to proceed with advanced development of a promising treatment for use in radiological or nuclear emergency situations.

September 24, 2013

Cancer Drug Developed by UAMS Professor Awarded FDA Approval

Ben Boulden

LITTLE ROCK — Valchlor, a breakthrough gel for treating lymphoma developed with the help of University of Arkansas for Medical Sciences (UAMS) College of Pharmacy Professor Peter Crooks, Ph.D., recently won marketing approval from the U.S. Food and Drug Administration.